Mutations in the kinase domain of epidermal growth factor receptor (EGFR) are associated with clinical responsiveness to gefitinib in patients with non-small-cell lung cancers (NSCLC). Recently, we have identified many novel EGFR mutations in NSCLC tissues. In this study, we found that gefitinib could suppress the tyrosine phosphorylation of most EGFR mutants better than the wild-type receptor. However, gefitinib had quite variable growth-suppressive effects on different EGFR mutantexpressing cells. All tested EGFR mutants have high basal phosphorylation at multiple tyrosine residues. Upon EGF stimulation, the mutated EGFRs did not have apparently stronger phosphorylation at tyrosines 845, 992, 1068, and 1173 than the wild-type receptor. However, stronger phosphorylation at tyrosine 1045 was observed in the S768I, L861Q, E709G, and G719S mutants. The E746-A750 deletion mutant was less responsive to EGF than the wild-type and other mutant receptors. The S768I, L861Q, E709G, and G719S mutants were refractory to EGFinduced ubiquitination and had more sustained tyrosine phosphorylation. E709G and G719S also lacked EGFinduced receptor downregulation. Our results indicate that, in addition to sensitivity to gefitinib, EGFR mutations also caused various changes in EGFR's regulatory mechanisms, which may contribute to the constitutive activation of EGFR mutants and oncogenesis in NSCLC.
Introduction
Epidermal growth factor receptor (EGFR, also named as ErbB1/HER1) is a member of the ErbB family. Binding of ligands to the extracellular domain of EGFR results in receptor oligomerization, activation of the receptor's tyrosine (Tyr) kinase activity, and phosphorylation of several C-terminal Tyr residues of EGFR (Holbro and Hynes, 2003) . In non-small cell lung cancers (NSCLC), EGFR is highly expressed (88-99%) (Rusch et al., 1993; Fontanini et al., 1998; Lai et al., 2001; Nicholson et al., 2001) . The overexpression of EGFR could be the result of gene amplification or enhanced gene transcription (Herbst and Bunn, 2003) . Interestingly, EGFR overexpression by itself is not prognostic of survival in NSCLC (Rusch et al., 1993; Fontanini et al., 1998; Hirsch et al., 2003) . The correlation between EGFR expression and poor survival, however, is more prominent when analysed along with the expression of its dimerization partner, ErbB2, or with its ligands, transforming growth factor-a (TGF-a) and EGF (Brabender et al., 2001; Herbst and Bunn, 2003) .
EGFR-tyrosine kinase (EGFR-TK) is a particularly promising therapeutic target for NSCLC because of its frequent overexpression in these tumors. Among EGFR-targeting agents, gefitinib is an orally active small molecule drug with evidence of antitumor activity in a range of cancers including NSCLC, as shown by phase I clinical trials (Herbst et al., 2002; Nakagawa et al., 2003) . Although the overall response rate to gefitinib was only 10-19% in patients with chemotherapy-refractory advanced NSCLC in multi-institutional phase II trials, a dramatical effect with rapid decrease of tumor size was found in a subgroup of patients (Fukuoka et al., 2003; Kris et al., 2003) . Recent reports had found that clinical responsiveness to gefitinib is closely associated with EGFR mutations in the kinase domain (Lynch et al., 2004; Paez et al., 2004) . These studies have also demonstrated that two mutations, L858R and delL747-P753insS, enhance EGF-dependent receptor activation and confer sensitivity to gefitinib on mutated EGFRs (Lynch et al., 2004; Paez et al., 2004) . These studies indicated that EGFR mutation, rather than EGFR overexpression, is the determining factor for responsiveness to gefitinib in NSCLC. It has also been shown that these two mutations enhance EGFinduced Akt activation, which subsequently prevent apoptosis in the mutant EGFR-expressing cells .
Previously, we have conducted mutational analysis of EGFR gene from exon 18 to exon 21 in a series of 101 surgically resected NSCLCs with no prior chemotherapy or gefitinib treatment (Huang et al., 2004) . We observed a high mutation rate for EGFR in Taiwanese patients (38.6%, 39/101), especially in adenocarcinoma (55.5%, 38/69), with complex mutation patterns. The L858R mutation and small deletions in exon 19 are the two major types of mutations observed at high frequencies (Huang et al., 2004) . In addition to these two types of mutations, various point mutations, insertions, and double mutants were also found (Huang et al., 2004) . Although they occurred at a lower frequency, changes at residues L861, S768, E709, G719, H835 and small insertions in exon 20 of EGFR gene have been repetitively observed in our and others' studies (Huang et al., 2004; Kosaka et al., 2004; Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) . Since EGFR mutations occur at different positions within the kinase domain, the biochemical properties of these mutations and the sensitivity of these novel mutants to gefitinib may not be identical. In this study, we examined the responsiveness of such novel EGFR mutants to gefitinib in cell cultures. We focused mainly on mutations that had been repetitively observed in NSCLC patients and on the EGFR double mutants (Table 1) . We found that gefitinib suppressed the phosphorylation of a majority of the newly identified EGFR mutations in our series of NSCLC better than that of the wild-type EGFR. However, the growth-suppressive effects of gefitinib on different mutant-expressing cells were quite variable. Additionally, mutations in the kinase domain caused constitutive phosphorylation of EGFR and changed its activation and regulatory mechanisms.
Results
Tyr phosphorylation of mutated EGFR is more sensitive to gefitinib We constructed expression vectors for the EGFR variants corresponding to mutations repetitively observed in NSCLC patients (Huang et al., 2004) . The sensitivity of wild-type EGFR and various mutants to gefitinib were first examined in transfected COS-7 cells. Overexpression of EGFR (or its mutants) caused strong Tyr phosphorylation of the receptor proteins. The inhibitory effects of gefitinib on EGFR and its derivatives were examined by Western blot analyses using an anti-phosphotyrosine antibody 4G10. The majority of EGFR mutants are more sensitive to gefitinib than wild-type EGFR, because lower concentrations of gefitinib were needed to suppress Tyr phosphorylation of the EGFR mutants (Figure 1) . Interestingly, the constitutively active EGFRvIII mutant was also hypersensitive to gefitinib when compared to wild-type EGFR (Figure 1 ). This result indicates that a mutation in the kinase domain of EGFR is not essential for acquiring hypersensitivity to gefitinib.
To verify this result in a system that is more relevant to NSCLC, we established permanently transfected cells for wild-type and mutated EGFRs using a H1299 NSCLC cell line. H1299 cells were selected because they express wild-type EGFR and respond well to EGF treatment (Amann et al., 2005) . Under regular culture condition (10% FCS), all EGFR mutants displayed a higher level of Tyr phosphorylation than did wild-type EGFR in H1299 cells (Figure 2a ). The inhibition of EGFR by gefitinib was observed by Western blot analysis, using both the 4G10 antibody and an antiphospho-EGFR (tyr1068) antibody (Figure 2b and c) . Similar to what we have observed in COS-7 cells, all EGFR variants, including the EGFRvIII mutant, are more sensitive to gefitinib than wild-type EGFR in H1299 cells. It was notable that, overall, higher concentrations of gefitinib were required to completely inhibit EGFR or its mutants in H1299 than in COS-7 cells (Figures 1 and 2 ). The underlying mechanism for this difference is not clear.
Mutated EGFRs have higher levels of basal receptor phosphorylation
We selected EGFR mutations that were frequently observed in NSCLC patients for further analysis. Individual clones that express a wild-type or mutated EGFR to comparable levels were isolated. Multiple clones for each mutant type were mixed to minimize variations across the clones. The expression levels of c A E746-A750 del/L861Q double mutant was also identified (Huang et al., 2004). wild-type and different EGFR mutants in the derived H1299 cell lines were similar by Western blotting analysis (Figure 3a) . Phosphorylations on different Tyr residues of EGFR variants were determined by Western blotting using specific antibodies (Figure 3b ). Under regular culture condition, all tested EGFR mutants displayed higher phosphorylation levels at Tyr residues 845, 992, 1068, and 1173 ( Figure 3b ) when compared to that in wild-type EGFR. However, stronger phosphorylation at Tyr 1045 was observed in mutants L858R, S768I, L861Q, and E709G, but not in E746-A750 deletion. G719S mutant only displayed a weak increase in Tyr 1045 phosphorylation when compared to wildtype EGFR under these conditions (Figure 3b ).
Mutated EGFRs have different patterns of Tyr phosphorylation in response to EGF stimulation
To examine the responsive patterns of EGFR mutants to ligand stimulation, H1299 derivatives were serumstarved for 12 h, and then treated with EGF (10 ng/ml). EGF-induced receptor phosphorylation at different time points was examined using various anti-phospho-EGFR antibodies and an anti-phosphotyrosine antibody 4G10 (Figure 4) . Consistent with the results in Figure 3 , all the EGFR mutant-expressing cells had a higher basal Tyr phosphorylation even in the absence of serum and exogenous EGF (Figure 4 ). The L861Q mutant had the strongest basal phosphorylation at all Tyr residues examined. Compared to vector-transfected cells, all the EGFR-transfected cells have higher receptor Tyr phosphorylation upon EGF stimulation. EGFR mutants did not have apparently stronger ligand-induced phosphorylation at Tyr residues 845, 992, 1068, and 1173 when compared to wild-type EGFR (Figure 4) . On the contrary, G719S mutant receptor had less EGFinduced phosphorylation at Tyr residues 845, 992, 1068, and 1173 than did wild-type EGFR (Figure 4) . Also, E746-A750 deletion mutant was only weakly responsive to EGF stimulation based on the slight increase in Tyr phosphorylation (Figure 4) . EGF-induced phosphorylation at Tyr 1045 had the most diverse patterns in wildtype EGFR and its mutants (Figure 4) . In response to EGF, S768I, L861Q and E709G mutants showed stronger phosphorylation at Tyr 1045. Additionally, EGF-induced Tyr 1045 phosphorylation in L858R and G719S mutants were slightly stronger than that in wild- Figure 1 EGFR mutants are more sensitive to gefitinib than is wild-type receptor in COS-7 cells. Expression vectors for myc-tagged, wild-type and mutated EGFRs were transfected into COS-7 cells. The transfected cells were cultured for 24 h and then treated with various doses of gefitinib (0, 0.02, 0.2, 2 mM) for 1 h. Cell extracts were prepared and subjected to Western blotting analyses. An antiphosphotyrosine antibody (4G10) and an anti-myc antibody (9E10) were used to detect the Tyr phosphorylation and expression levels of p175 EGFR, respectively. The intensity of the signals was determined by densitometry. The calculated EGFR activity was the ratio of Tyr phosphorylation over EGFR expression levels. The levels of EGFR activity in the absence of gefitinib were considered as 100%. type receptor. In contrast, E746-A750 deletion mutant showed a delayed and weak Tyr 1045 phosphorylation, which was comparable to that in wild-type EGFR. These results indicated that, in addition to sensitivity to gefitinib, mutations in EGFR kinase domain might also change the activation patterns of mutated EGFR in response to EGF stimulation. We also examined the potential additive effect in EGFR double mutations. Unfortunately, the expression levels between EGFR single and double mutants were quite different in cloned cells. A satisfactory comparison was possible only in one case. By normalizing the receptor phosphorylation levels with receptor expression levels, we found that an additive effect might exist between L858R and E709G mutations in the absence of EGF stimulation. No additive effects were observed in L858R/E709G mutant in response to EGF (Supplementary Figure 1 ).
S768I, L861Q, E709G, and G719S EGFR mutants are refractory to phosphorylation-mediated ubiquitination
The appearance of constitutive Tyr 1045 phosphorylation in EGFR mutants S768I, L861Q, and E709G is very interesting because phosphorylation at this residue is known to recruit Cbl to EGFR and lead to Cblmediated receptor multi-ubiquitination, internalization, and degradation (Levkowitz et al., 1999; Haglund et al., 2003; Mosesson et al., 2003) . Hyperphosphorylation on Tyr 1045 could be caused by preferential phosphorylation on this site by the mutated receptors or by defects in the removal of phosphorylated receptors. To test the first possibility, we performed in vitro kinase assays for wild-type and mutated EGFRs. The results in Figure 5 show that mutants S768I, L861Q, and E709G do not phosphorylate Tyr 1045 better than wild-type EGFR, indicating that the higher levels of phosphorylation at Tyr 1045 in these mutants were probably not a result of an increase in enzyme-substrate preference.
To examine whether hyperphosphorylation at Tyr 1045 (and other residues) was due to defects in receptor ubiquitination and/or subsequent degradation, H1299 derivatives were transfected with a vector-encoding HA-EGF: -2 5 10 -2 5 10 -2 5 10 -2 5 10 -2 5 10 -2 5 10 -2 5 10 -2 5 10 (min) Figure 4 Mutated EGFRs have distinct patterns of Tyr phosphorylation in response to EGF stimulation. Parental and various EGFR-transfected H1299 cells were cultured in serum-free condition for 12 h and then were treated with EGF (10 ng/ml). The cells were collected at the indicated time points and were subjected to cell extract preparation and Western blot analyses. The various Tyr phosphorylations on EGFR were examined using five anti-phospho-EGFR antibodies and an anti-phosphotyrosine antibody (4G10).
The expression levels of EGFR were examined using an anti-myc antibody (9E10). tagged ubiquitin. The transfected cells were treated with or without EGF, and the myc-tagged EGFR proteins were immunopreceipiated and examined for their ubiquitination status. We found that L858R and E746-A750 deletion mutants showed a slight increase in ubiquitination when compared to wild-type EGFR ( Figure 6 ). In contrast, S768I, L861Q, E709G, and G719S mutants did not have detectable ubiquitination, despite strong phosphorylation at Tyr 1045, either in the presence or absence of EGF stimulation ( Figure 6 ). This result suggests that EGFR mutants S768I, L861Q, E709G, and G719S might have a defect or defects in their ubiquitination processes.
S768I, L861Q, E709G, and G719S mutants have more sustained Tyr phoshorylation than that of wild-type receptor In light of the defect of receptor ubiquitination in S768I, L861Q, E709G and G719S mutant, we performed a kinetic study of Tyr 1045 phosphorylation in wild-type and mutant EGFRs from the 15-min time point to 6 h post EGF stimulation. Similar to the result in Figure 4 , S768I, L861Q, E709G, and G719S mutants had stronger Tyr 1045 phosphorylation than that in wild-type, L858R and E746-A750 deletion receptors (Figure 7a ). Tyr 1045 phosphorylation in wild-type EGFR and deletion mutant peaked at the 15-min time point and decreased over the experimental period. In contrast, Tyr 1045 phosphorylation in L858R, S768I, L861Q, E709G, and G719S mutants peaked between the 15-min and 1-h time points and decreased at slower rates. Mutants S768I, L861Q, and E709G had the most sustained Tyr 1045 phosphorylation among the EGFR mutants. This result suggested that the negatively regulatory mechanism of receptor phosphorylation might be impaired in mutant EGFRs.
In the kinetic study, we did not observe apparent decreases in EGFR levels as reported by others. It was likely that EGFR proteins produced from the transfected genes efficiently replenished the EGFR pools; therefore, no changes in the protein levels could be detected. To test this possibility and to examine the downregulation of EGFR proteins, we pretreated the cells with puromycin before the EGF stimulation to inhibit de novo protein synthesis. At this experimental condition, we detected evident EGF-induced downregulation of EGFR proteins in L858R, del, S768I, and L861Q mutants. These mutant proteins had decrease rates similar to that of the wild-type receptor (Figure 7b) . Differently, EGF-induced receptor downregulations were much slower in E709G and G719S mutant-expressing cells (Figure 7b ). This result indicated that E709G and G719S EGFR mutants might have defective mechanisms in downregulation of receptor proteins. We also examined ligand-induced EGFR The cells were subjected to cell extract preparation, and the EGFR proteins was immunoprecipitated using an anti-Myc antibody (9E10). The ubiquitination levels of immunoprecipitated EGFRs were examined by Western blotting using an anti-HA antibody. The same membranes were stripped and reblotted using an anti-pEGFR (Tyr 1045) and an anti-myc antibody to examine the phosphorylation and protein levels of the immunoprecipitated EGFRs, respectively.
internalization by observing the uptake of rhodamineconjugated EGF in H1299 derivatives upon a temperature shift. All EGFR mutant-expressing cells internalized rhodamine-EGF when shifted from 41C to 371C, suggesting that these mutations did not affect receptor internalization (Supplementary Figure 2) .
Gefitinib has variable growth-inhibitory effects in cells expressing different EGFR mutants
Our biochemical examinations (Figures 1 and 2) showed that mutant EGFRs were more sensitive to gefitinib than were the wild-type cells. However, these mutant receptors have different activation patterns and distinct regulatory mechanisms (Figures 3-7) . We also performed growth-inhibition assays to examine the biological responses of EGFR mutant-expressing cells to gefitinib. Unfortunately, all the EGFR (wild-type or mutant)-expressing H1299 derivatives showed similar growth inhibition in responses to gefitinib (Supplementary Figure 3 ). This result could be due to the lack of EGFR dependence in the transfected H1299 cells or to the intrinsic resistance to gefitinib in the host cells (Amann et al., 2005) . To overcome these problems, we used 32D cells, an IL-3-dependent myeloid cell line, for our assays. EGFR-transfected 32D cells can use the EGF/EGFR pathway for survival and mitogenic signaling. In the absence of IL-3 and the presence of EGF, EGFR-expressing 32D cells become EGF dependent (Pierce et al., 1988) . With this experimental system, we found that 32D cells expressing L858R, E746-A750 deletion, and G719S mutants were most sensitive to a Figure 7 S768I, L861Q, E709G, and G719S mutants have more sustained Tyr phpshorylation than that of wild-type receptor. Parental and various EGFR-transfected H1299 cells were cultured in serum-free condition for 12 h and then were treated with EGF (50 ng/ml; a) or were pretreated with puromycin (5 mg/ml) followed by EGF treatment (50 ng/ml; b). The cells were collected at the indicated time points and were subjected to cell extract preparation and Western blot analyses. The Tyr 1045 phosphorylations on EGFR were examined using the specific anti-phospho-EGFR antibodies. The expression levels of EGFR and actin were examined using an anti-myc antibody (9E10) and anti-b actin antibody (AC-15). The intensity of the signals was determined by densitometry. The phosphorylation levels of EGFR in (a) were normalized by the myc-EGFR protein levels and the EGFR expression levels in (b) were normalized by the expression levels of b actin.
gefitinib. They were not viable at the lowest dose (0.5 mM) of inhibitor after a 3-day culture. L861Q mutant-expressing cells were also more sensitive to gefitinib than the 32D cells harboring wild-type EGFR, but to a less extent. On the contrary, S768I and E709G mutant-expressing cells were slightly more resistant to gefitinib than the wild-type EGFR-expressing cells (Figure 8 ). Interestingly, for unknown reasons, gefitinib at 0.5 mM had reproducible growth-promoting ability in 32D cells expressing wild-type, S768I or E709G EGFR proteins. Taken together, our data indicated that gefitinib might have variable growth-inhibitory effects in cells containing different mutant EGFRs.
Discussion
Mutations in the kinase domain of EGFR have been linked to clinical responsiveness to gefitinib in NSCLC patients (Huang et al., 2004; Kosaka et al., 2004; Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) . Previous biochemical analyses have been limited to the L858R mutation and various in-frame deletions, such as delL747-P753insS and delL747-S752, in exon 19 of the EGFR gene (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004; Sordella et al., 2004) . In this study, we have examined the biochemical properties of EGFR variants, including several double mutations, that were observed in NSCLC patients (Huang et al., 2004) . Changes at residues L861, S768, E709, G719, L833, H835, L838 and small insertions in exon 20 (EAFQins), although occurred at lower frequencies, were included since they have been repetitively observed in previous studies (Huang et al., 2004; Kosaka et al., 2004; Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) . We found that gefitinib could suppress the Tyr phosphorylations of all EGFR mutants more effectively than wild-type EGFR, either in COS-7 cells or in H1299 NSCLC cells (Figures  1 and 2 ). Many mechanisms can cause hypersensitivity to gefitinib in mutated EGFRs. The mutations may increase binding affinity between EGFR and the inhibitor or may enhance the negative regulatory mechanisms of EGFR, including degradation and/or dephosphorylation, leading to hypersensitivity to gefitinib subsequently. The mutations in this study were located at distinct positions in the EGFR kinase domain, but our results reveal that all mutations could cause higher sensitivity to gefitinib. Thus, increased binding affinity between mutant receptors and the inhibitor per se may not be the major cause of hypersensitivity as previously suggested (Lynch et al., 2004; Paez et al., 2004) . A recent study has also shown that clinically identified mutations in EGFR kinase domain cause only small changes in binding affinity to gefitinib (increases or decreases within threefold), and this suggests that a stronger interaction of mutated EGFRs to the inhibitor may not be the major mechanism for the clinical responsiveness in NSCLC patients (Fabian et al., 2005) . Additionally, we found that the EGFRvIII mutant, which does not have a mutation in the kinase domain, was also more sensitive to gefitinib than wild type EGFR in transfected cells (Figures 1 and 2) . Collectively, the evidence suggests that a mutation in EGFR kinase domain is not essential for obtaining hypersensitivity to gefitinib, and that hypersensitivity to gefitinib in mutated EGFR may be derived from another property (or properties) that are introduced by the mutations. A thorough investigation into various functional pathways is warranted to clarify this issue.
All mutant EGFRs that were characterized in this study also had higher levels of basal phosphorylation than wild-type EGFR (Figures 2, 3 and 4) . Although overexpression might have contributed to the ligandindependent activation of the mutant receptors, this mechanism should not be the only cause for constitutive activation of the EGFR mutants. The expression level of wild-type EGFR in our system was comparable to that of mutant EGFRs, but very low levels of Tyr phosphorylation were detected in wild-type EGFRexpressing H1299 cells in the absence of ligands (Figure 4) . Therefore, the constitutive activation of mutant EGFR must be derived from biochemical changes caused by the mutations. Since Tyr phosphorylation is critical for the biological activity of EGFR (Holbro and Hynes, 2003) , these mutants might have stronger ligand-independent growth-promoting ability than wild-type EGFR. Interestingly, none of the mutated EGFRs had apparently stronger phosphorylation at Tyr residues 845, 992, 1068, and 1173 in response to EGF when compared with wild-type EGFR (Figure 4) . Actually, the E746-A750 deletion and G719S mutants were less responsive to EGF than wild-type EGFR (Figure 4 ). These data indicate that these EGFR mutations do not lead to hyper-responsiveness to EGF. The role of EGFR phosphorylation at Tyr 1045 in ligand-induced receptor ubiquitination, endocytosis, and degradation was demonstrated previously (Levkowitz et al., 1999; Mosesson et al., 2003) . Although the necessity of Tyr 1045 phosphorylation and receptor ubiquitination in EGFR internalization has been questioned in several studies (Duan et al., 2003; Jiang and Sorkin, 2003; Sigismund et al., 2005) , our data showed that S768I, L861Q, and E709G mutants had very high levels of Tyr 1045 phosphorylation (Figures 4, 6, and 7) . Mutant G719S had lower EGF-induced phosphorylation at other Tyr residues, but had stronger phosphorylation at Tyr 1045, than wild-type receptor (Figures 4  and 6 ). These four mutants, unlike wild-type EGFR, did not have detectable ubiquitination in the presence or absence of EGF stimulation (Figure 6 ). Regardless of their phosphorylation and ubiquitination properties, we found no apparent difference in receptor internalization among wild-type and mutant EGFRs (Supplementary Figure 2) . This result is consistent with previous reports showing that EGFR ubiquitination is not essential for receptor internalization (Duan et al., 2003; Jiang and Sorkin, 2003; Sigismund et al., 2005) . However, S768I, L861Q, E709G, and G719S mutants did have more sustained Tyr phosphorylation than wild-type receptor in response to EGF (Figure 7A ), suggesting a defect(s) in the negatively regulatory mechanism. Moreover, E709G and G719S mutants also lacked EGF-induced receptor protein downregulation (Figure 7b ).
Although our biochemical examinations (Figures 1  and 2 ) might imply that majority of the EGFR mutations could lead to hypersensitivity to gefitinib in mutation-harboring tumor cells, our result in growth inhibition by gefitinib showed otherwise (Figure 8) . In different EGFR variant-expressing 32D cells, only cells harboring L858R, E746-A750 deletion, and G719S mutants were clearly more sensitive to gefitinib than wild-type EGFR-expressing cells. Cell expressing the L861Q mutant were also more sensitive, but to a less extent. Cells expressing S768I and E709G mutant were actually more resistant to gefitinib than cells expressing the wild-type receptor (Figure 8 ). Interestingly, S768I and E709G were among the mutants that lacked ubiquitination and also had sustained Tyr phosphorylation in response to EGF stimulation. It is unclear whether these properties are related to the relative resistance to gefitinib in cells harboring these two mutants. Currently we are unable to correlate particular mutations, other than L858R and deletion mutants, to treatment responses to gefitinib due to the scarcity of these mutations in reported cases. However, clinical responses to gefitinib have been reported in patients with mutations at residues L861 and G719 (Huang et al., 2004; Kosaka et al., 2004; Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004) . Other than the properties of EGFR mutants, the distinct genetic backgrounds in the NSCLC cells (or patients) may also affect the biological responses. It was noted that no preferential inhibition on growth by gefitinib was observed in EGFR mutantexpressing H1299 cells despite the universal gefitinib hypersensitivity of EGFR mutant proteins in these cells (Supplementary Figure 3) . It is possible that the growth or survival of the host cells were not dependent on the transfected EGFR genes. It is also possible that H1299 cells are more resistant to gefitinib in nature (Amann et al., 2005) , and the introduction of EGFR mutants could not change the cellular responses to this chemical. A recent report regarding NSCLC patients with postoperative tumor recurrence also showed that two patients with the L858R mutation responded poorly to gefitinib, while most patients with the L858R mutation in that series were associated with a good response to gefitinib (Mitsudomi et al., 2005) . All these data indicate that other host (cell or human) factors can affect biological responses to gefitinib.
Taken together, our results suggests that, in addition to hypersensitivity to gefitinib, mutations in EGFR kinase domain also caused various changes in EGFR's regulatory mechanisms, which may contribute to the constitutive activation of mutated receptors and oncogenesis in NSCLC. Although the majority of EGFR mutants were more sensitive to gefitinib by measuring receptor Tyr phosphorylation, it does not warrant hypersensitivity at the cellular level.
Materials and methods

Cell culture and transfection
Cos-7 cells were cultured in DMEM medium supplemented with 10% fetal calf serum (FCS) plus penicillin (50 U/ml) and streptomycin (50 mg/ml). Parental H1299 cell line and its derivatives were maintained in RPMI-1640 medium supplemented with 10% FCS plus penicillin (50 U/ml) and streptomycin (50 mg/ml). Myeloid cell line 32D was provided by Dr Ling-Mei Wang (National Health Research Institutes, Taiwan) and was cultured in RPMI-1640 medium supplemented with 10% FCS, 5% WEHI-3 conditioned medium, L-glutamine (2 mM) plus penicillin (50 U/ml) and streptomycin (50 mg/ml). The transfection in Cos-7 and H1299 cells were performed using the lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. The transfection of 32D cells was performed using an electroporator (BTX, Holliston, MA, USA) according to the manufacturer's instruction. The transfected H1299 and 32D cells were subjected to 500 mg/ml of zeocin (Invitrogen, Carlsbad, CA, USA) selection for 1 week to establish permanently transfected cells. The expressions of transfected EGFRs were confirmed by Western blot analyses.
Plasmid constructions DNA fragment encoding wild-type EGFR was PCR-amplified from an EGFR-GFP-expressing vector kindly provided by Dr Ming-Chi Hung (M.D. Anderson Cancer Center, Houston, TX, USA), restriction enzyme digested, and inserted into a pcDNA4/TO/myc-His B vector (Invitrogen, Carlsbad, CA, USA) between the HindIII and XhoI sites. All the EGFR point mutation variants were generated using the QuickChange sitedirected mutagenesis kit (Stratagene, La Jolla, CA, USA). Pfuturbo enzyme (Stratagene)-based PCR amplification was used to generate the individual DNA fragments with or without the mutation sequences in the EGFRvIII, E746-750 deletion, and EAFQ insertion mutants. The DNA fragments were then restriction enzyme-digested and inserted into the pcDNA4/ TO/myc-His B vector. The expression vectors for all the EGFR variants were verified by DNA sequencing. All EGFR variants had a Myc-tagged epitope at their carboxyl termini. A DNA fragment encoding ubiquitin was PCR-amplified using specific primers and a cDNA pool derived from H1299 cells as templates. The DNA fragment was then enzyme-digested and inserted between BamHI and EcoRI sites of a pCR3.1-HA (hemagglutinin) vector.
Reagents and Antibodies
Gefitinib was provided by AstraZeneca UK Limited (London, England). EGF was purchased from Sigma-RBI (Natick, MA, USA). The anti-myc monoclonal antibody was prepared from a culture of hybridoma clone 9E10. The anti-phosphotyrosine antibody 4G10 was purchased from Upstate Biotechnology (Waltham, MA, USA). The anti-EGFR and anti-phospho-EGFR antibodies (to phosphotyrosines 845, 992, 1045, and 1068) were purchased from Cell Signaling Technology (Beverly, MA, USA). The anti-phsopho-EGFR (Tyr 1173) antibody and anti-b actin antibody (AC-15) were purchased from Santa Cruz (Santa Cruz, CA, USA) and Sigma-Aldrich (St Louis, MO, USA), respectively. The peroxidase-conjugated anti-mouse IgG secondary antibody was purchase from Peirce (Rockford, IL, USA). The other chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA).
Cell extracts preparation, immunoprecipitation, and kinase assays Whole-cell lysate was prepared by suspending 2 Â 10 6 cells in 200 ml of lysis buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 1% Triton -X-100, 0.5% deoxycholate, 0.1% SDS, 2 mg/ml leupeptin, 5 mg/ml aprotinin, 1 mM PMSF, and 1 mM Na 3 VO 4 ). The cell lysates were kept on ice and vigorously vortexed every 5 min for four times. The lysate was cleared by centrifugation at 15 000 g for 10 min, and the supernatant was collected for further analysis or stored at À801C. Immunoprecipitation was performed as described (Chen et al., 2002) with modifications. Transfected myc-tagged EGFRs in cell extracts were precipitated by incubation with an anti-myc monoclonal antibody (9E10) and protein G-agarose beads in lysis buffer with continuous rotation at 41C. The precipitate were washed three times with lysis buffer, and once with kinase buffer (20 mM 4-morpholinepropane-sulfonic acid (MOPS; pH 7.6), 2 mM EGTA, 10 mM MgCl 2 , 1mM dithiothrietol (DTT), 0.1% Triton X-100, and 0.1 mM Na 3 VO 4 ), then mixed with 50 ml of kinase buffer containing 800 mM of ATP. The kinase reaction was performed at 371C for 30 min, and then terminated by adding SDS sampling buffer. The reaction mixtures were heated at 951C for 5 min and analysed by SDS-PAGE and Western blot analyses.
Western blot analyses
Equal amounts of cell extracts (50-100 mg) or immunoprecipitated complexes of various samples were resolved by SDS-PAGE (8 or 10%), and then transferred to polyvinylidene difluoride (PVDF) membrane (Millipore, Bedford, MA, USA). The membrane was first incubated in TBST buffer (20 mM Tris (pH 7.5), 135 mM NaCl, and 0.1% Tween 20) with 5% milk powder (or 2% BSA), then incubated with a primary antibody (dilution of antibodies were performed according to the manufacturer's instructions), washed, and blotted with secondary antibody conjugated with horseradish peroxidase (1:1000 dilution). The membrane was then developed in SuperSignal reagent (Pierce, Rockford, IL, USA) and exposed to X-ray films.
Cell viability assay Cell viability was examined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. In brief, 4000 32D cells in 50 ml of medium (containing 40 ng/ml of EGF) were seeded in each well of 96-well plates. In all, 50 ml of medium containing different doses of gefitinib (2-16 mM) were then added to the well. Every treatment was quadruplicated in an assay. The cells were cultured for 3 days before adding 10 ml of MTT solution (5 mg/ml) to each well. The reaction was performed at 371C for 3 h and was terminated by adding 100 ml of solublizing solution (50% dimethyl formamide and 10% SDS in water). The result was determined by measuring the absorbance at 570 nm using a micro-plate reader.
Abbreviations
EGF, epidermal growth factor; EGFR, EGF receptor; FCS, fetal calf serum; HA, hemagglutinin; IC50, concentration of 50% inhibition; NSCLC, non-small-cell lung cancer; TGF-a, transforming growth factor-a; Tyr, tyrosine.
